Core Metadata
| identifier | |
| source |
https://www.sec.gov/
|
| blake2b |
6eb07ed876f075343be9fd09338f0c96fe4ab993287cf381ee8d2fd87987c401fd075fc6eebdf6fabbbff6a8d04ebc1e51b5df9bfac39b6871dc6faac10292b3
|
| id |
0001104659/0001104659-15-077262/21
|
| format |
text/html
|
| size |
84363
|
| dataset_id |
edgar
|
| meta_url | |
| download_url |
Additional Metadata
JSON
{
"/ACCESSION-NUMBER": [
"0001104659-15-077262"
],
"/DATE-OF-FILING-DATE-CHANGE": [
"20151109"
],
"/FILING-DATE": [
"20151109"
],
"/PERIOD": [
"20150930"
],
"/PUBLIC-DOCUMENT-COUNT": [
"12"
],
"/TYPE": [
"10-Q"
],
"FILER/BUSINESS-ADDRESS/CITY": [
"PRINCETON"
],
"FILER/BUSINESS-ADDRESS/PHONE": [
"609-683-1880"
],
"FILER/BUSINESS-ADDRESS/STATE": [
"NJ"
],
"FILER/BUSINESS-ADDRESS/STREET1": [
"101 POOR FARM ROAD"
],
"FILER/BUSINESS-ADDRESS/ZIP": [
"08540-1715"
],
"FILER/COMPANY-DATA/ASSIGNED-SIC": [
"2834"
],
"FILER/COMPANY-DATA/CIK": [
"0001261249"
],
"FILER/COMPANY-DATA/CONFORMED-NAME": [
"AGILE THERAPEUTICS INC"
],
"FILER/COMPANY-DATA/FISCAL-YEAR-END": [
"1231"
],
"FILER/COMPANY-DATA/IRS-NUMBER": [
"000000000"
],
"FILER/COMPANY-DATA/STATE-OF-INCORPORATION": [
"DE"
],
"FILER/FILING-VALUES/ACT": [
"34"
],
"FILER/FILING-VALUES/FILE-NUMBER": [
"001-36464"
],
"FILER/FILING-VALUES/FILM-NUMBER": [
"151215971"
],
"FILER/FILING-VALUES/FORM-TYPE": [
"10-Q"
],
"FILER/MAIL-ADDRESS/CITY": [
"PRINCETON"
],
"FILER/MAIL-ADDRESS/STATE": [
"NJ"
],
"FILER/MAIL-ADDRESS/STREET1": [
"101 POOR FARM ROAD"
],
"FILER/MAIL-ADDRESS/ZIP": [
"08540-1715"
],
"description": "IDEA: XBRL DOCUMENT",
"filename": "R8.htm",
"sequence": "21",
"type": "XML"
}
Would you train on this document?
Document Viewer
text/markdown
| **Fair Value Measurements** | 9 Months Ended | |-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| || | **Fair Value Measurements** | | | Fair Value Measurements | 3. Fair Value Measurements ASC 820, Fair Value Measurements and Disclosures, describes the fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: · Level 1 — Quotes prices in active markets for identical assets and liabilities. The Company’s Level 1 assets and liabilities consist of cash and cash equivalents. · Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities. The Company has no Level 2 assets or liabilities. · Level 3 — Unobservable inputs that are supported by little or no market data and which require internal development of assumptions about how market participant price the fair value of the assets or liabilities. The Company’s Level 3 liabilities consist of the warrant liability. The Company is required to mark the value of its warrant liability to market and recognize the change in valuation in its statements of operations each reporting period. The following table sets forth the Company’s financial instruments measured at fair value by level within the fair value hierarchy as of September 30, 2015 and December 31, 2014. Level 1 Level 2 Level 3 September 30, 2015 Assets: Cash and cash equivalents $ 39,359,262 $ — $ — Total assets at fair value $ 39,359,262 $ — $ — Liabilities: Common stock warrants $ — $ — $ 251,247 Total liabilities at fair value $ — $ — $ 251,247 The significant assumptions used in preparing the option pricing model for valuing the Company’s warrants as of September 30, 2015 include (i) volatility (75.0%), (ii) risk free interest rate of 1.15% (estimated using treasury bonds with a 4.25 year life), (iii) strike price ($6.00) for the common stock warrants, (iv) fair value of common stock ($6.74) and (v) expected life (4.25 years). The following is a rollforward of the fair value of Level 3 warrants: Beginning balance at December 31, 2014 $ 296,048 Change in fair value (44,801 ) Ending balance at September 30, 2015 $ 251,247 Level 1 Level 2 Level 3 December 31, 2014 Assets: Cash and cash equivalents $ 40,135,102 $ — $ — Total assets at fair value $ 40,135,102 $ — $ — Liabilities: Common stock warrants — — 296,048 Total liabilities at fair value $ — $ — $ 296,048 The significant assumptions used in preparing the option pricing model for valuing the Company’s warrants as of December 31, 2014 include (i) volatility (104.8%), (ii) risk free interest rate of 1.68% (estimated using treasury bonds with a 5 year life), (iii) strike price ($6.00) for the common stock warrants, (iv) fair value of common stock ($6.14) and (v) expected life (five years). There were no transfers between Level 1, 2 or 3 during 2014 or 2015. If the Company’s estimates regarding the fair value of its warrants are inaccurate, a future adjustment to these estimated fair values may be required. Additionally, these estimated fair values could change significantly. | | X | |--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | - References No definition available. + Details**Name:**us-gaap_FairValueDisclosuresAbstract**Namespace Prefix:**us-gaap_**Data Type:**xbrli:stringItemType**Balance Type:**na**Period Type:**duration | | X | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | - Definition The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13504-108611Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611 + Details**Name:**us-gaap_FairValueDisclosuresTextBlock**Namespace Prefix:**us-gaap_**Data Type:**nonnum:textBlockItemType**Balance Type:**na**Period Type:**duration |